Bionomics Ltd (BNO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bionomics Ltd (BNO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013166
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bionomics Ltd (Bionomics) is a biopharmaceutical company that focuses on the development of treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer’s disease. Its pipeline products include BNC210, BNC 105, BNC101, and BNC375. The company uses various technology platforms including MultiCore; ionX; and CSC Rx Discovery Platform for discovering highly active, functional therapeutic antibodies and small molecule candidates that target cancer stem cells. It works in partnership with Merck & Co., Inc.; Cancer Therapeutics CRC; Genmab A/S; Laboratory Corporation of America; Genetic Technologies Limited for drug discovery and development. Bionomics is headquartered in Thebarton, South Australia, Australia.

Bionomics Ltd (BNO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bionomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bionomics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Bionomics Acquires Assets of Prestwick Chemical for USD0.34 million 10
Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 11
Venture Financing 12
Eclipse Therapeutics Secures US$2 Million In Seed Financing 12
Eclipse Therapeutics Secures US$2.8 Million In Venture Financing 13
Licensing Agreements 14
Bionomics Enters into Licensing Agreement with Merck for BNC375 14
Bionomics Extends Licensing Agreement with Merck 15
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody 16
Equity Offering 17
Bionomics Raises USD9 Million in Private Placement of Shares 17
Bionomics Completes Rights Issue Of Shares For US$12.7 Million 18
Bionomics Completes Private Placement For US$15 Million 19
Asset Transactions 20
Bionomics Acquires Assets of Prestwick Chemical for USD0.34 million 20
Bionomics Completes Sale Of Thebarton Research Facility For US$4 Million 21
Acquisition 22
Bionomics Acquires Eclipse Therapeutics, Developer Of Cancer Drugs, For US$10 Million 22
Start-up Australia Ventures Sold 18.8% Stake in Bionomics 24
Bionomics Ltd – Key Competitors 25
Bionomics Ltd – Key Employees 26
Bionomics Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 16, 2017: Bionomics Reports Full Year Financial Results for 2017 28
Aug 09, 2016: Bionomics Reports Full Year Financial Results 29
Corporate Communications 30
Aug 09, 2016: Board Changes and Conclusion of Governance Review 30
Product News 31
01/09/2017: Bionomics Provides Update on BNC-101 Clinical Program At 2017 San Francisco Biotech Showcase 31
Clinical Trials 32
Apr 03, 2017: Bionomics Presents Promising BNC101 Data at American Association for Cancer Research Conference 32
Oct 25, 2016: Bionomics to Present at International Biotechnology Symposium 33
Apr 04, 2016: Bionomics Initiates Phase 1 Study Of BNC101 For Treatment Of Metastatic Colorectal Cancer 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Bionomics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bionomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bionomics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Bionomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bionomics Acquires Assets of Prestwick Chemical for USD0.34 million 10
Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 11
Eclipse Therapeutics Secures US$2 Million In Seed Financing 12
Eclipse Therapeutics Secures US$2.8 Million In Venture Financing 13
Bionomics Enters into Licensing Agreement with Merck for BNC375 14
Bionomics Extends Licensing Agreement with Merck 15
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody 16
Bionomics Raises USD9 Million in Private Placement of Shares 17
Bionomics Completes Rights Issue Of Shares For US$12.7 Million 18
Bionomics Completes Private Placement For US$15 Million 19
Bionomics Acquires Assets of Prestwick Chemical for USD0.34 million 20
Bionomics Completes Sale Of Thebarton Research Facility For US$4 Million 21
Bionomics Acquires Eclipse Therapeutics, Developer Of Cancer Drugs, For US$10 Million 22
Start-up Australia Ventures Sold 18.8% Stake in Bionomics 24
Bionomics Ltd, Key Competitors 25
Bionomics Ltd, Key Employees 26
Bionomics Ltd, Subsidiaries 27

★海外企業調査レポート[Bionomics Ltd (BNO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Regeneron Pharmaceuticals Inc (REGN):企業の製品パイプライン分析
    Summary Regeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, meta …
  • Tubacero S. de RL de CV:企業の戦略・SWOT・財務分析
    Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report Summary Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Flower Orthopedics Corp:医療機器:M&Aディール及び事業提携情報
    Summary Flower Orthopedics Corp (Flower Orthopedics) is a medical equipment provider that offers orthopedic devices. The company offers instrument kits which include K-wire kits, olive wire kits, guide wire kits, drill bit kits, lag screw kits, cannulated drill bits, trials and cannulated countersin …
  • Capio AB:企業の戦略・SWOT・財務情報
    Capio AB - Strategy, SWOT and Corporate Finance Report Summary Capio AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Tutunski Kombinat AD Prilep:企業の戦略・SWOT・財務分析
    Tutunski Kombinat AD Prilep - Strategy, SWOT and Corporate Finance Report Summary Tutunski Kombinat AD Prilep - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Sicon Ltd:企業の戦略・SWOT・財務情報
    Sicon Ltd - Strategy, SWOT and Corporate Finance Report Summary Sicon Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)-製薬・医療分野:企業M&A・提携分析
    Summary Tianjin Zhongxin Pharmaceutical Group Corp Ltd (TZPG) manufactures and markets traditional Chinese medicine, western medicine and health products. The company offers Chinese patent medicines, Chinese medicinal materials, western medicines, dietary supplements, pharmaceutical raw materials an …
  • New Zealand Oil & Gas Ltd (NZO):企業の財務・戦略的SWOT分析
    Summary New Zealand Oil & Gas Ltd (NZOG) is an oil and gas exploration, development and production company. It acquires, explores, and develops crude oil and natural gas properties. NZOG’s producing assets include Maari and Manaia fields, Kupe gas and light oil field, and Sampang PSC. The company pa …
  • Prakash Industries Ltd (PRAKASH):企業の財務・戦略的SWOT分析
    Summary Prakash Industries Ltd (PIL) is a power and steel company. The company’s business activities include mining, steel and power, plastic and wind power. Its mining business division offers explores, acquires and develops iron ore and coal properties. PIL’s steel and power business division prov …
  • Redhall Group Plc:企業の戦略・SWOT・財務情報
    Redhall Group Plc - Strategy, SWOT and Corporate Finance Report Summary Redhall Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Reata Pharmaceuticals Inc (RETA):企業の財務・戦略的SWOT分析
    Summary Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription fa …
  • Lansdowne Oil & Gas plc (LOGP):企業の財務・戦略的SWOT分析
    Summary Lansdowne Oil & Gas Plc (Lansdowne Oil & Gas) is an independent oil and gas exploration and production company. The company acquires, explores and develops crude oil and natural gas appraisals in the North Celtic Sea Basin offshore in southern Ireland. It develops Barryroe Field in the North …
  • Arthur J. Gallagher & Co:戦略・SWOT・企業財務分析
    Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report Summary Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Power Corporation of Canada:企業の戦略・SWOT・財務分析
    Power Corporation of Canada - Strategy, SWOT and Corporate Finance Report Summary Power Corporation of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Sabre Corporation (SABR):企業の財務・戦略的SWOT分析
    Sabre Corporation (SABR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Trellis Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Trellis Bioscience Inc (Trellis) is a drug development company that discovers and develops human antibody therapeutics for the treatment of bacterial and viral infectious diseases and cancer indications. The company’s clinical candidate includes TRL1068, which targets and disintegrates bacte …
  • ERG Power Generation SpA:企業の戦略的SWOT分析
    ERG Power Generation SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Calimmune Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Calimmune Inc (Calimmune), a subsidiary of CSL Behring Australia Pty Ltd, is a novel gene therapy program developer. The company’s ex vivio autulogus cell therapy includes CAL-1 and CAL-H. Its CAL-1 offers cell therapies for HIV AIDS. Calimmune’s CAL-H cell therapy provides himoglobinopathie …
  • Carl Zeiss Meditec AG (AFX)-医療機器分野:企業M&A・提携分析
    Summary Carl Zeiss Meditec AG (Carl Zeiss Meditec), a division of Carl Zeiss AG, an integrated medical technology company which operates in the fields of ophthalmology, neuro/ENT surgery and surgical ophthalmology. It provides comprehensive packages of solutions for the diagnosis and treatment of ey …
  • Valio Ltd:企業の戦略的SWOT分析
    Valio Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆